Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱(chēng) 貨號(hào) 規(guī)格
Recombinant Staphylococcus aureus 30S ribosomal protein S6 (rpsF) CSB-YP756925SKV
CSB-EP756925SKV
CSB-BP756925SKV
CSB-MP756925SKV
CSB-EP756925SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus 5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase (metE), partial CSB-YP756926SKV
CSB-EP756926SKV
CSB-BP756926SKV
CSB-MP756926SKV
CSB-EP756926SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Lipase 2 (lip2) CSB-YP756927SKV
CSB-EP756927SKV
CSB-BP756927SKV
CSB-MP756927SKV
CSB-EP756927SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Protein esaB (esaB) CSB-YP756928SKV
CSB-EP756928SKV
CSB-BP756928SKV
CSB-MP756928SKV
CSB-EP756928SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Protein essA (essA), partial CSB-YP756929SKV
CSB-EP756929SKV
CSB-BP756929SKV
CSB-MP756929SKV
CSB-EP756929SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Sensory transduction protein lytR (lytR) CSB-YP756930SKV
CSB-EP756930SKV
CSB-BP756930SKV
CSB-MP756930SKV
CSB-EP756930SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Formate acetyltransferase (pflB), partial CSB-YP756931SKV
CSB-EP756931SKV
CSB-BP756931SKV
CSB-MP756931SKV
CSB-EP756931SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus FMN-dependent NADH-azoreductase (azoR) CSB-YP756932SKV
CSB-EP756932SKV
CSB-BP756932SKV
CSB-MP756932SKV
CSB-EP756932SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Arginine biosynthesis bifunctional protein ArgJ (argJ) CSB-YP756933SKV
CSB-EP756933SKV
CSB-BP756933SKV
CSB-MP756933SKV
CSB-EP756933SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Probable siderophore biosynthesis protein SbnA (sbnA) CSB-YP756934SKV
CSB-EP756934SKV
CSB-BP756934SKV
CSB-MP756934SKV
CSB-EP756934SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus HTH-type transcriptional regulator SAR0097 (SAR0097) CSB-YP756935SKV
CSB-EP756935SKV
CSB-BP756935SKV
CSB-MP756935SKV
CSB-EP756935SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Ribosomal RNA large subunit methyltransferase H (rlmH) CSB-YP756936SKV
CSB-EP756936SKV
CSB-BP756936SKV
CSB-MP756936SKV
CSB-EP756936SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus DNA gyrase subunit A (gyrA), partial CSB-YP756937SKV
CSB-EP756937SKV
CSB-BP756937SKV
CSB-MP756937SKV
CSB-EP756937SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xenopus tropicalis Abhydrolase domain-containing protein FAM108C1 (fam108c1) CSB-YP756938XBF
CSB-EP756938XBF
CSB-BP756938XBF
CSB-MP756938XBF
CSB-EP756938XBF-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xenopus tropicalis Grainyhead-like protein 3 homolog (grhl3), partial CSB-YP756939XBF
CSB-EP756939XBF
CSB-BP756939XBF
CSB-MP756939XBF
CSB-EP756939XBF-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xenopus tropicalis Protein BCCIP homolog (bccip) CSB-YP756940XBF
CSB-EP756940XBF
CSB-BP756940XBF
CSB-MP756940XBF
CSB-EP756940XBF-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xenopus laevis Mitoferrin-2A (slc25a28-a), partial CSB-YP756941XBE1
CSB-EP756941XBE1
CSB-BP756941XBE1
CSB-MP756941XBE1
CSB-EP756941XBE1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xenopus laevis Desumoylating isopeptidase 1 (pppde2) CSB-YP756942XBE
CSB-EP756942XBE
CSB-BP756942XBE
CSB-MP756942XBE
CSB-EP756942XBE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xenopus laevis Bromodomain-containing protein 9 (brd9), partial CSB-YP756943XBE
CSB-EP756943XBE
CSB-BP756943XBE
CSB-MP756943XBE
CSB-EP756943XBE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xenopus laevis Fumarylacetoacetate hydrolase domain-containing protein 2 (fahd2) CSB-YP756944XBE
CSB-EP756944XBE
CSB-BP756944XBE
CSB-MP756944XBE
CSB-EP756944XBE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開(kāi)發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開(kāi)發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶(hù)提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€(xiàn)留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>